Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Direct antiplatelet effects of the novel engineered human apyrase APT-102

Dec. 21, 2004

Alfimeprase shows efficacy in the treatment of occluded CVADs

Dec. 15, 2004

Suntory describes novel agents for the treatment of thrombosis

Dec. 9, 2004

New factor Xa inhibitors in early development at Merck

Dec. 3, 2004

Trigen and Eurand to develop controlled-release TGN-167

Nov. 26, 2004

Bayer signs development agreement for longer-acting Kogenate

Nov. 24, 2004

TGN-255 investigated in two phase I studies

Nov. 22, 2004

Factor Xa inhibitors claimed by Bristol-Myers Squibb

Nov. 11, 2004

Nuvelo to gain worldwide rights to alfimeprase

Nov. 4, 2004

New factor XIa inhibitors identified by BMS researchers

Nov. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...